Head of CMC Drug Development and consulting services practice. Tony has 30 years of senior management experience in drug development, cGMP manufacturing and commercialization; including hands-on plant management, budgeting and strategic planning. His experience spans a broad range of small molecule and biologic dosage forms and all aspects of technical and manufacturing operations from active pharmaceutical ingredient (API) through fill and finishing operations for clinical and commercial launch; including: Synercid®, Abelcet®, Myocet®, Taxotere®, Nasacort®, Lovenox®, Thymitaq®, lixivaptan, and rM-CSF.
Anthony has held positions of increasing responsibility at CardioKine Inc, Eximias Pharmaceuticals, Rhone Poulenc Rorer, Bristol Myers Squibb, Aventis, The Liposome Company and Enzo BiochemInc. Tony is an inventor on numerous patents and a founder of DSI. He received a BS in Biology from Rutgers University.